JWZ-8-103
Based on 1 Customer Validation
JWZ-8-103 is an orally active PRLX-93936 (HY-119264) analog and TRIM21-targeting molecular glue. JWZ-8-103 increases the thermal stability of TRIM21. JWZ-8-103 promotes a robust and rapid interaction between TRIM21 and NUP98 (apparent EC50 = ∼20 μM for TRIM21 PRYSPRY and NUP98 APD). JWZ-8-103 has anti-cancer effects against pancreatic cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.04%
- CAS. Nr.: 3110272-60-8
- Formel: C21H22ClFN4O2
- Molecular Weight:416.88
-
Speicherung:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Oxygen Sensing Compound Library
HY-L045
-
Ubiquitination Compound Library
HY-L050
-
Orally Active Compound Library
HY-L061
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Molecular Glue Compound Library
HY-L137
-
Metabolic Enzyme Compound Library
HY-L146
-
Mitophagy Compound Library
HY-L180
-
MCE Bioactive Compound Library
HY-L001V
-
Amino Acid Metabolism Compound Library
HY-L189
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
Biologische Aktivität
apparent EC50 = ∼20 μM (ternary complex formation between TRIM21 PRYSPRY and NUP98 APD in the presence of JWZ-8-103)[1]
Chemical Information
-
CAS. Nr. 3110272-60-8
-
Appearance Solid
-
Molecular Weight 416.88
-
Formel C21H22ClFN4O2
-
Color White to off-white
-
SMILES
CCOC1=CC(Cl)=CC=C1N2C(C3=CC(F)=CC=C3N=C2CN4CCNCC4)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (239.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Yuan L, et al. Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex. Cancer Discov. 2025 Dec 2;15(12):2505-2529. [Content Brief]
[2]. Steven M, et al. Trim21-targeted compounds and uses thereof. WO2025255442A1. WIPO (PCT). 2025-06-06.
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3988 mL | 11.9939 mL | 23.9877 mL | 59.9693 mL |
| 5 mM | 0.4798 mL | 2.3988 mL | 4.7975 mL | 11.9939 mL | |
| 10 mM | 0.2399 mL | 1.1994 mL | 2.3988 mL | 5.9969 mL | |
| 15 mM | 0.1599 mL | 0.7996 mL | 1.5992 mL | 3.9980 mL | |
| 20 mM | 0.1199 mL | 0.5997 mL | 1.1994 mL | 2.9985 mL | |
| 25 mM | 0.0960 mL | 0.4798 mL | 0.9595 mL | 2.3988 mL | |
| 30 mM | 0.0800 mL | 0.3998 mL | 0.7996 mL | 1.9990 mL | |
| 40 mM | 0.0600 mL | 0.2998 mL | 0.5997 mL | 1.4992 mL | |
| 50 mM | 0.0480 mL | 0.2399 mL | 0.4798 mL | 1.1994 mL | |
| 60 mM | 0.0400 mL | 0.1999 mL | 0.3998 mL | 0.9995 mL | |
| 80 mM | 0.0300 mL | 0.1499 mL | 0.2998 mL | 0.7496 mL | |
| 100 mM | 0.0240 mL | 0.1199 mL | 0.2399 mL | 0.5997 mL |
JWZ-8-103 Related Classifications
HY-180654 Related Classifications
Powered by Bioz